Study on the safety and efficacy of FUAS treatment in patients with adenomyosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083988

Enrollment

Unknown

Registered

2024-05-08

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyopathy

Interventions

Adenomyopathy group:No reintervention

Uterine fibroids Group:No reintervention

Eligibility

Sex/Gender

Female

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: Study group (adenomyosis group) : Aged 25 to 45 years, adenomyosis was diagnosed by imaging examination (MRI, pelvic ultrasound) or endoscopy, and the lesion was located in the uterine wall =30mm. Control group (uterine fibroids group) : Age 25 ~ 45 years old, in line with the diagnostic criteria for uterine fibroids, confirmed by cervical cytology, gynecology and ultrasound examination;

Exclusion criteria

Exclusion criteria: In addition to HIFU treatment of adenomyopathy and uterine fibroids exclusion criteria (1) Combined with other gynecological diseases; (2) Previous history of HIFU treatment; (3) The patient has other uncontrolled systemic diseases;

Design outcomes

Primary

Measure	Time frame
IL-6;TNF-a;E-cadheri;beta-catenin;Integrin a?ß3;Flt KDR;Estrogen receptor;HOXA-10;MMP-9;	—

Countries

China

Contacts

Public ContactLi yuan

Nanchuan District People's Hospital of Chongqing

767638406@qq.com+86 159 7896 2993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026